Immunic AG
Clinical Trials
48
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: IMU-838 tabletsDrug: Placebo matching IMU-838 tablets
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 1050
- Registration Number
- NCT05201638
- Locations
- 🇺🇸
HonorHealth Research Institute - Bob Bove Neuroscience Institute, Scottsdale, Arizona, United States
🇺🇸Neuro of Central Florida, Altamonte Springs, Florida, United States
🇺🇸Healthcare Innovations, Coral Springs, Florida, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: IMU-838 tabletsDrug: Placebo matching IMU-838 tablets
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 1050
- Registration Number
- NCT05134441
- Locations
- 🇺🇸
Xenoscience, Inc., 21st Century Neurology, Phoenix, Arizona, United States
🇺🇸Bradenton Research Center, Bradenton, Florida, United States
🇺🇸Reliant Medical Research, LLC, Miami, Florida, United States
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 18
- Registration Number
- NCT05124795
- Locations
- 🇬🇧
Institute of Cancer Research, London, United Kingdom
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo matching IMU-838
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 450
- Registration Number
- NCT05054140
- Locations
- 🇺🇸
Dr. Sonia Kalirao, Coral Springs, Florida, United States
🇺🇸Collier Neurologic Specialists, Naples, Florida, United States
🇺🇸Prof. James Scott, Ormond Beach, Florida, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 234
- Registration Number
- NCT04379271
- Locations
- 🇧🇬
Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria
🇧🇬UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria
🇩🇪University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany
- Prev
- 1
- 2
- Next